Literature DB >> 7845670

The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.

C P Mansur1, B Marcus, S Dalal, E J Androphy.   

Abstract

The E6 proteins of specific cancer-associated human papillomaviruses (HPVs) complex with and mediate degradation of the cellular anti-oncogene p53 in vitro. A critical property of p53 is its ability to stimulate transcription from promoters containing its recognition sequence. HPV E6, mutant p53 proteins, and several DNA tumor virus oncogenes inhibit the transcriptional activity of wild-type p53. In this report, the structural requirements for the interaction between HPV 16 E6 and p53 were examined both in vivo and in vitro. p53-stimulated transcription was efficiently inhibited by wild-type HPV 16 E6 and E6 mutants competent for p53 binding and degradation. A series of p53 deletions and hybrid proteins with heterologous DNA binding, dimerization and transactivation domains were analysed for transcriptional interaction with HPV 16 E6 to determine the domains of p53 required for transcriptional inhibition. These chimeric proteins were also analysed for E6 binding and E6-mediated degradation in vitro. In both assays, complex formation with E6 was mediated through the amino-terminal 345 amino acids of p53 without a specific requirement for its C-terminus. Hybrid proteins containing residues 161-345 of p53 also bound E6, but this segment of p53 was not susceptible to E6 induced proteolysis. A second region of p53, within its N-terminal 160 aa, is required for E6 induced degradation of complexed p53. Taken together, these results suggest that the complex formation between E6 and p53 is not mediated through the C-terminus of p53 and that binding and degradation are separable.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7845670

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Authors:  M S Rodriguez; J M Desterro; S Lain; D P Lane; R T Hay
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

2.  The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.

Authors:  J T Zilfou; W H Hoffman; M Sank; D L George; M Murphy
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

3.  Viral oncoproteins discriminate between p53 and the p53 homolog p73.

Authors:  M C Marin; C A Jost; M S Irwin; J A DeCaprio; D Caput; W G Kaelin
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

4.  Regulation of Mdm2-directed degradation by the C terminus of p53.

Authors:  M H Kubbutat; R L Ludwig; M Ashcroft; K H Vousden
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

Review 5.  Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate.

Authors:  J Doniger; S Muralidhar; L J Rosenthal
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

6.  Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells.

Authors:  Y Liu; J J Chen; Q Gao; S Dalal; Y Hong; C P Mansur; V Band; E J Androphy
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

7.  Genetic analysis of high-risk e6 in episomal maintenance of human papillomavirus genomes in primary human keratinocytes.

Authors:  Regina B Park; Elliot J Androphy
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation.

Authors:  X Li; P Coffino
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

9.  Human cytomegalovirus mtrII oncoprotein binds to p53 and down-regulates p53-activated transcription.

Authors:  S Muralidhar; J Doniger; E Mendelson; J C Araujo; F Kashanchi; N Azumi; J N Brady; L J Rosenthal
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

Review 10.  HPV-p53-miR-34a axis in HPV-associated cancers.

Authors:  Jiezhong Chen; Kong-Nan Zhao
Journal:  Ann Transl Med       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.